Glycolysis is usually considered as a paradigm metabolic pathway, due to the fact that it is present in most organisms, and also because it is the pathway by which an important nutrient, glucose, is consumed. Far from being completely understood, the regulation of this pathway witnessed several important progresses during the last few years. One of these is the discovery of fructose 2,6-bisphosphate, a potent stimulator of phosphofructokinase and inhibitor of fructose-1,6-bisphosphatase. Originally found in the liver during the course of a study on the mechanism by which glucagon acts on gluconeogenesis, this compound is now recognized as a major element in the control of glycolysis and/or gluconeogenesis in many cell types and in various organisms. The other finding is that of a regulatory protein that modulates the activity of glucokinase, the enzyme that phosphorylates glucose in the liver and in the beta cells of pancreatic islets.
The central role of glycolysis
In the first four decades of the 20th century, the pioneering work of such famous names as Harden, Young, Embden, Meyerhof and Warburg led to the identification of the intermediates of glycolysis and of the enzymes catalysing its different steps [1] . Glycolysis thus became the first metabolic pathway to be deciphered, which is one of the reasons for its fame. Another reason is that it is present in almost all cell types, except for a few bacteria that developed alternative means of fermenting glucose. The ubiquity of glycolysis reflects the important role played by glucose in cell physiology. Glucose is unique in that its metabolism can furnish ATP even in the absence of 02. Furthermore, this hexose is an essential substrate for tissues such as the brain and the retina, as well as for mammalian erythrocytes. Finally, the most prevalent metabolic disease, diabetes mellitus, is to a large extent, a perturbation of glucose metabolism.
During the last 40 years the interest of investigators in the field of metabolism has focused on the regulation of biochemical pathways. Control enzymes have been * Presented as tile Minkowski Lecture, EASD Meeting Prague, Czechoslovakia 1992 identified and their properties investigated. The importance of covalent modification has been recognized and the existence of second messengers has been estabfished. The purpose of this review is to describe two discoveries pertaining to the regulation of glycolysis. The first is that of fructose 2,6-bisphosphate, which is now known to play a central role in the regulation of glycolysis in most eukaryotic cells, and the second is that of a regulatory protein that affects the activity of glucokinase, an enzyme present in the liver and in pancreatic islets of mammals.
Fructose 2,6-bisphosphate

Discovery
The liver plays an important role in the control of glycaemia. Following a carbohydrate rich diet, this organ is able to consume glucose, which is first stored as glycogen and secondarily metabolized to glycolytic products and lipids. More importantly, the liver is able to secrete glucose during fasting [reviewed in 2] . This glucose is formed by depolymerization of glycogen, or by gluconeogenesis from various compounds such as lactate, pyruvate, glycerol and several amino acids. Gluconeogenesis, which is Fig.1 . The pathways of glycolysis and gluconeogenesis, and their regulation by fructose 2,6-bisphosphiite. For the sake of clarity, cosubstrates have not been indicated the reverse of glycolysis, is different at only three levels ( Fig. 1 ). These are: 1) the interconversion between glucose and glucose 6-phosphate, catalysed by glucokinase in the glycolytic direction, and by glucose 6-phosphatase in the gluconeogenic direction; 2) the interconversion between fructose 6-phosphate and fructose 1,6-bisphosphate, operated by phosphofructokinase (PFK 1) and by fructose-l,6-bisphosphatase (FBPase 1); 3) the interconversion between phosphoenolpyruvate and pyruvate, implicating one enzyme, pyruvate kinase, in the glycolytic direction and two enzymes, pyruvate carboxylase and phosphoenolpyruvate carboxykinase, in the gluconeogenic direction. Each of these seven enzymes catalyses a unidirectional reaction and is therefore a potential target for flux control.
Glucagon is a pancreatic hormone, a major effect of which is to stimulate the release of glucose by the liver. It not only promotes glycogen breakdown, but also stimulates gluconeogenesis and inhibits glycolysis, as was recognized in the early 1960s [3] . Like the effect on glycogen metabolism, the effect on gluconeogenesis is mediated by cyclic AMP [4] , but its precise mechanism remained elusive for a number of years. Measurements of the concentrations of metabolites identified the interconversions between pyruvate and phosphoenolpyruvate, and between fructose 1,6-bisphosphate and fructose 6-phosphate as the targets for the regulation by glucagon [3, 5, 6] . The discovery that liver pyruvate kinase was an interconvertible enzyme, which was inactivated upon phosphorylation by cAMP-dependent protein kinase offered an explanation for the first crossover [reviewed E. Van Schaffingen: Glycolysis revisited in 7] . This inactivation causes an inhibition of the conversion of phosphoenolpyruvate to pyruvate, which, in turn, raises the concentration of phosphoenolpyruvate and favours its conversion to fructose 1,6-bisphosphate (Fig. 1) .
Flux measurements using isotopically labelled substrates indicated that glucagon also caused in the intact cell a decrease in the flow of metabolites through phosphofructokinase [8] [9] [10] [11] . The possibility that this enzyme was interconvertible, was seriously considered when in 1979, several groups of investigators showed that the activity of phosphofructokinase, when measured at subsaturating concentration of fructose 6-phosphate, was decreased in extracts of liver cells that had been exposed to glucagon [12] [13] [14] [15] . No effect was observed at saturating concentrations of fructose 6-phosphate, indicating that treatment with the hormone only changed the affinity of the enzyme for its substrate.
It turned out, however, that the change in the kinetic properties induced by the glucagon treatment disappeared if the extracts were carefully filtered on Sephadex G-25 or if the enzyme was partially purified [11] , two processes that separate proteins from the small molecules present in the extracts. Gel filtration actually decreased the apparent affinity for fructose 6-phosphate of the phosphofructokinase present in control extracts, without significantly affecting the kinetics of the enzyme present in extracts of cells treated with glucagon. In addition, protein-free extracts of control fiver cells were found to stimulate phosphofructokinase, whereas similar extracts prepared from cells treated with glucagon exerted no stimulation. These results indicated that the effect of glucagon to reduce the activity of phosphofructokinase was mediated by the decrease in the concentration of a lowmolecular-weight effector of this enzyme [11] . Work from the laboratory of Pilkis [16] also indicated that the change in the kinetic properties of phosphofructokinase was not due to a covalent modification and also disclosed a lowmolecular-weight stimulator. Furuya and Uyeda [17] also found evidence of the presence of an "activation factor" in liver.
The new effector of phosphofructokinase was characterized in our laboratory as an extremely acid-labile diphosphoric ester, and eventually identified as fructose 2,6-bisphosphate on the basis that it was quantitatively converted to stoichiometric amounts of fructose 6-phosphate and inorganic phosphate upon incubation under mild acid conditions. Furthermore, acid hydrolysis caused the appearance of a reducing power that was exactly accounted for by the liberated fructose 6-phosphate. This indicated that fructose 6-phosphate was bound to a second molecule of phosphate in the intact stimulator of phosphofructokinase [18] .
That no other chemical group entered in the native structure was proved by the demonstration that an effector having all the properties of the natural one was formed upon incubation of fructose 6-phosphate in the presence of concentrated phosphoric acid at 0 ~ [19] . Fructose 2,6-bisphosphate was then synthesized [20] [21] [22] in millimolar amounts from fructose 1,6-bisphosphate and its properties could be further investigated.
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Fructose 2,6-bisphosphate is the most potent stimulator of phosphofructokinase not only from liver, but also from all animal tissues [reviewed in [23] [24] [25] [26] [27] . These enzymes are characteristically inhibited by high concentrations of ATP and display a sigmoidal saturation curve for their other substrate, fructose 6-phosphate. At micromolar or submicromolar concentrations, fructose 2,6-bisphosphate stimulates the activity by antagonizing the inhibition exerted by ATP and increasing the affinity for fructose 6-phosphate.
The diphosphate sugar is also a positive effector for phosphofructokinases from yeast and from other fungi [reviewed in 26] . In plants, the conversion of fructose 6-phosphate to fructose 1,6-bisphosphate is catalysed not 583 only by the classic phosphofructokinase that uses ATP as a phosphate donor, but also by PPi-PFK, which uses inorganic pyrophosphate (PPi) instead of ATE As originally shown by Sabularse and Anderson [28] , plant PPi-PFK is greatly stimulated by fructose 2,6-bisphosphate. The remarkable sensitivity of the potato tuber enzyme to this ellector permitted the development of an assay allowing one to measure less than 1 picomole of this effector [29] .
Fructose 2,6-bisphosphate is also an inhibitor of fructose-l,6-bisphosphatase from animal tissues and from fungi, as well as of the cytosolic enzyme from plants [reviewed in [23] [24] [25] [26] [27] . The inhibition is stronger at low concentrations of fructose 1,6-bisphosphate than at high concentrations. Furthermore fructose 2,6-bisphosphate changes the shape of the saturation curve from a hyperbola to a sigmoid, and acts synergically with the allosteric effector AMR Through its opposite effects on phosphofructokinase and fructose 1,6-bisphosphatase ( Fig. 1) , the novel effector can act as a switch: when its concentration is elevated, it favours glycolysis and inhibits gluconeogenesis. Conversely, when its concentration is low, glycolysis is turned off and gluconeogenesis proceeds without inhibition.
Biosynthesis and biodegradation, and their control by hormones and metabolites
Fructose 2,6-bisphosphate is formed from fructose 6-phosphate and ATP by a special phosphofructokinase called phosphofructokinase 2 (PFK 2) and hydrolysed to fructose 6-phosphate and inorganic phosphate by fructose-2,6-bisphosphatase (FBPase 2) [reviewed in 2, 23-26, [30] [31] [32] [33] . The two enzymes are part of a single bifunctional protein, several isozymes of which have now been described. The liver isozyme, the first to be studied, is a substrate for cyclic AMP-dependent protein kinase (Fig. 2) . Its phosphorylation causes the inactivation of PFK 2 and the activation of FBPase 2 and, therefore, the disappearance of fructose 2,6-bisphosphate, as observed when liver cells are treated with glucagon or other agents that cause an increase in the concentration of cAMR The two activities of the bifunctional enzymes are also controlled by the concentration of some metabolites, principally fructose 6-phosphate, a substrate for PFK 2 and a powerfulinhibitor for FBPase 2, and glycerol 3-phosphate, an inhibitor of PFK 2 and a stimulator for FBPase 2. The regulatory role of fructose 6-phosphate is best illustrated by the effect of glucose, which increases the concentrations of fructose 6-phosphate and of fructose 2,6-bisphosphate in the liver, and hence increases glycolysis and inhibits gluconeogenesis [2] . Glucose also causes an increase in the concentration of fructose 2,6-bisphosphate in other cells, including the beta cells of pancreatic islets [34] .
In streptozotocin-diabetes, the concentration of fructose 2,6-bisphosphate in the liver is low, in accordance with the elevated gluconeogenic flux. The low concentration of the bisphosphate ester is presumably the result of the elevated glucagon concentration and the low insulin concentration in the plasma. These hormonal changes are expected to cause not only an increase in the phosphorylation [26] . Fructose 2,6-bisphosphate is, like cyclic AMR a signal molecule, which is formed from ubiquitous compounds by a highly regulated enzyme. It is not itself on a major metabolic pathway, but is used as an integrator of metabolism. Originally, cyclic AMP was probably a "hunger signal", which signified the lack of glucose [36] . By contrast, fructose 2,6-bisphosphate signifies that glucose is abundant and can be used by glycolysis, and that gluconeogenesis must be stopped [23] .
The regulatory protein of glucokinase
Glucokinase, a special form of hexokinase
The phosphorylation of glucose in animal tissues is catalysed by four different hexokinases (EC 2.7.1.1). Hexokinase I, II and III display a high affinity for glucose (Kin < 0.2 mmol/1) and are inhibited by concentrations of glucose 6-phosphate in the physiological range Ireviewed in 37]. Their activity can therefore be adjusted to the rate at which glucose 6-phosphate is utilized by tissues.
The fourth hexokinase, glucokinase [reviewed in 38] has distinctive kinetic properties: it displays a sigmoidal saturation curve for glucose [39] , and its half saturating concentration of substrate (S0z) is about 10 mmol/1, a value slightly above the concentration of glucose in the plasma of normal subjects. Since glucokinase is not inhibited by micromolar concentrations of glucose 6-phosphate, it is generally accepted that the activity of this enzyme is controlled on a short-term basis by the concentration of glucose. Accordingly glucokinase is present only in two cell types that have to respond physiologically to changes in the glucose concentration. These cell types are the parenchymal cells of the liver and the beta cell of pancreatic islets [reviewed in 38, 40, 41] .
The glucokinase gene comprises two different promoters, separated by at least 10 kilobase pairs. The most upstream of the two promoters is used in the pancreas and the other in the liver and the two resulting mRNAs differ at their 5' end. The deduced sequence of the predominant islet enzyme differs from the liver isozyme by less than 10 amino acids at the N terminus. It is not known if this difference has any effect on the physiological function of glucokinase [reviewed in 42].
state of PFK2/FBPase 2, but also reduce the expression of glucokinase (see below) and hence decrease the glucose 6-phosphate and fructose 6-phosphate concentration [35] .
Importance and pathophysiological implications
Fructose 2,6-bisphosphate is now recognized as a major control element for switching from glycolysis to gluconeogenesis after glucagon treatment [2] . It has also been
Effect or fructose on the phosphorylation of glucose in isolated hepatocytes
The rate of glucose phosphorylation can be monitored in cell suspensions by the release of tritium from [2-3H] water [43] . In 1979, Clark and co-workers [44] found that the detritiation of glucose was stimulated about three-fold when 2.5 mmol/1 fructose was added to a suspension of isolated hepatocytes. This effect remained without explanation for about 10 years. See section mechanism of action for details 585 hibition exerted by fructose 6-phosphate is partial and that it is antagonized by fructose 1-phosphate, which acts competitively vs fructose 6-phosphate. Other experiments showed that the regulatory protein inhibited glucokinase competitively with respect to glucose [46] .
The regulatory protein was purified to homogeneity by a procedure involving several chromatographic steps and identified as a 62 kDa polypeptide. Since the molecular mass of the native protein is = 60 kDa, these results indicated that the regulatory protein is a monomer [47] .
Mechanism of action
When this problem was reinvestigated [43] , it was found that fructose increased the apparent affinity of glucokinase for its sugar substrate, the S0.5 for glucose decreasing from 15-20 mmol/1 to 9-10 mmol/1. Furthermore, the ketohexose was found to act at very low concentrations, a half-maximal effect being reached at = 50 gmol/1. The effect of fructose was almost maximal 5 min after its addition, and it was readily lost when the cells were washed free of the ketose. These results indicated that the increase in glucokinase activity was not due to synthesis of new protein but to a more rapid process, such as a change in the concentration of an allosteric effector or in the extent of a covalent modification [45] .
It was also found that sorbitol, at similar concentrations as fructose, and D-glyceraldehyde at about 10-fold higher concentrations, stimulated detritiation whereas dihydroxyacetone or glycerol had no such effect [43] . This suggested that the stimulation resulted from the formation of a metabolite that could be produced from fructose, sorbitol or D-glyceraldehyde, although not from dihydroxyacetone or glycerol. As can be deduced from Figure 3 , the best candidate was fructose 1-phosphate, an intermediate of fructose and sorbitol metabolism, which can also be formed from D-glyceraldehyde and dihydroxyacetonephosphate by reversal of the reaction catalysed by aldolase.
Discovery of the regulatory protein
Fructose 1-phosphate was found to stimulate glucokinase in cell-flee extracts but had no effect on this enzyme when it had been partially purified by anion-exchange chromatography [46] . These results indicated that, in order to be sensitive to fructose 1-phosphate, glucokinase required the presence of a substance from which it was separated during purification. Accordingly, we found that the fractions eluted from an anion-exchange column at approximately 80 mmol/1 KC1 contained an inhibitor of glucokinase, whose effect was cancelled by fructose 1-phosphate (Fig.4) .
The inhibitor was a protein, as indicated by its heatand trypsin-sensitivity and by its molecular mass of =60kDa. Its effect was largely dependent on the presence of fructose 6-phosphate, which, by itself, did not inhibit glucokinase. Figure 5 illustrates the fact that the inIt was conceivable that the regulatory protein inhibited glucokinase indirectly, for example by catalysing the conversion of fructose 6-phosphate to an hypothetical inhibitor. The fact that no inhibitor was formed when regulatory protein was incubated with fructose 6-phosphate eliminated this possibility. Furthermore, the regulatory protein did not appear to cause a stable modification in the kinetic properties of glucokinase, i.e. a modification that would persist after separation of the two proteins [47] . This indicated that the regulatory protein was not acting as a modifying enzyme, that would catalyse a covalent modification.
The possibility that the regulatory protein inhibited glucokinase merely by forming a complex with this enzyme was tested by measuring the apparent molecular mass of glucokinase by centrifugation in sucrose gradient. In the absence of regulatory protein, the mass of glucokinase was about 55 kDa and this value was unchanged when glucokinase was centrifuged together with regulatory protein in the absence of fructose 6-phosphate. However, it almost doubled in the simultaneous presence of regulatory protein and fructose 6-phosphate, although not when fructose 1-phosphate was also included. Conversely glucokinase caused an increase in the apparent molecular mass of the regulatory protein in the presence of fructose 6-phosphate. These results indicated that fructose 6-phosphate promoted the formation of a complex between glucokinase and regulatory protein, and that fructose 1-phosphate inhibited the formation of this complex [47] .
The next problem was to understand how these phosphate esters could affect the association of the two proteins. Since neither fructose 6-phosphate nor fructose 1-phosphate affected the kinetic properties of glucokinase in the absence of regulatory protein, they most likely acted by binding to the latter. Accordingly the regulatory protein was found to bind up to about 1 mol of fructose 1-phosphate or of sorbitol 6-phosphate (an inhibitor that is about 5 times more potent than fructose 6-phosphate) per mol [48] . The binding of fructose 1-phosphate and of sorbitol 6-phosphate are mutually competitive, suggesting that both types of effectors bind to one single site .....
On the basis of these results the model shown in Figure 6 was proposed. According to this model, the regulatory protein exists under two different conformations, one (R) which can bind glucokinase and inhibit this enzyme, and the other (R'), which cannot. Fructose 6-phosphate binds to conformation R, and fructose 1-phosphate, to conformation R'. In the absence of inhibitor and activator, the ratio R/R' is equal to 1/15, accounting for the modest inhibition exerted by the regulatory protein in the absence of effector [46, 49] . Fructose 6-phosphate increases this ratio, thus reinforcing the inhibition exerted by the regulatory protein. Fructose 1-phosphate antagonizes the fructose 6-phosphate effect by trapping the regulatory protein in the R' conformation.
The model shown in Figure 6 is reminiscent of that proposed for the regulation of cyclic AMP-dependent protein kinase by its regulatory subunit [reviewed in 50]. In both cases, the free catalytic subunit is active and loses activity upon association to the regulatory subunit, the effect of ligands such as fructose 1-phosphate or cyclic AMP being to prevent the association. One difference between the two systems is that the holoenzyme is an heterotetramer in the case of cyclic AMP dependent protein kinase and a heterodimerin the case of glucokinase. Another difference is that no ligand is required to promote the association in the case of cyclic AMP-dependent protein kinase. Finally, the association constant of the glucokinase/regulatory protein complex is lower than that of protein kinase, explaining that the regulatory protein easily dissociates from glucokinase following homogenization of the liver [46] .
Kinetic studies fully supported the model shown in Figure 6 [51] . In addition they showed that the regulatory protein binds to glucokinase at a site distinct from the catalytic site, despite the fact that it inhibits glucokinase competitively with respect to glucose [49] .
Physiological implications
The liver cell contains under all conditions at least 10 gmol/1 fructose 6-phosphate. Since in the absence of fructose, it does not contain fructose 1-phosphate [52] , glucokinase is inhibited by the regulatory protein. This explains that, in intact cells, the apparent affinity of glucokinase is lower than that of the pure enzyme. The fact that fructose and other compounds that give rise to fructose 1-phosphate restore the affinity to the expected level is in accordance with this interpretation [45, 52] . This type of regulation not only occurs in isolated hepatocytes, but also in vivo [53] . In anaesthetized rats, the rate of glucose phosphorylation, as measured by the detritiation of [2-3H] glucose administered via the portal vein, amounts to --0.6 gmol. rain-1. g-1, i. e. about 40 % of the glucokinase activity that can be measured in a cell-free extract at the concentration of glucose present in the liver. Fructose, when injected in a peripheral vein, stimulated this rate up to about 2.5-fold in fed and overnight fasted rats, a maximal effect being observed at a dose of 50 mg/kg. Fructose was also active when administered by intragastric infusion, a dose of 20 mg/kg causing the rate to increase twofold. When extrapolated to man, this dose of fructose corresponds to only between i and 2 g of pure fructose.
The novel mode of regulation of glucokinase accounts for the fact that fructose administration causes a moderate hypoglycaemia in anaesthetised rats or in perfused livers [54, 55] , and for the fact that fructose increases the conver-E. Van Schaffingen: Glycolysis revisited sion of radiolabelled glucose to glycogen [44, 56] . Since fructose is present in most foods of vegetable origin that also contain glucose, it can play the role of a signal that stimulates the consumption of alimentary glucose by the liver.
The regulatory protein in pancreatic islets
In pancreatic beta cells, glucokinase plays an important role in the control of the glycolytic flux and, consequently, in the control of insulin secretion [57] . The following data indicate that the regulatory protein is present also in this cell type [58] : 1) glucokinase from islet tissue is inhibited by the regulatory protein from rat liver; 2) in islet extracts, the rate of glucose phosphorylation is stimulated by fructose 1-phosphate; 3) in intact islets, the rate of detritiation of [5-3H] glucose is stimulated by D-glyceraldehyde, which causes a significant increase in the intracellular concentration of fructose 1-phosphate. Fructose is, however, unable to stimulate the phosphorylation of glucose, because fructokinase activity is extremely low in this tissue. The physiological role of the regulatory protein in islets remains unknown.
Is the regulatory protein implicated in the development of diabetes?
One rare subtype of non-insulin-dependent diabetes, maturity-onset diabetes of the young (MODY) is distinctive clinically because it has an early onset and is consistently inherited as an autosomal dominant trait [59] . It was recently shown that in some families, MODY is linked with the glucokinase gene [60] . Further analysis showed that, in those families, missense or non-sense mutations were present in the glucokinase gene and cosegregated with MODY [61, 62] . This clearly indicated that decreased expression of functional glucokinase in the liver and in the beta cells is implicated in this disease. We speculate that mutations in the gene encoding the regulatory protein could also be responsible for diab etes, if they result in the synthesis of an "hyperactive" protein. The mode of inheritance of this type of diabetes is expected to be also dominant.
